MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2011 | Meritage Pharma | Venture Round | 6.5M |
5/2003 | Acorda Therapeutics | Series B | 55.3M |
5/2008 | SAI Life Sciences | Private Equity Round | 20M |
8/2008 | Peplin | Private Equity Round | 24M |
12/2018 | Entrada Therapeutics | Series A | 59M |
11/2017 | Semma Therapeutics | Series B | 0 |
11/2006 | Elixir Pharmaceuticals | Series C | 0 |
10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
6/2005 | Amphora Discovery | Series D | 9.6M |
4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
7/2009 | iPierian | Venture Round | 11.5M |
7/2005 | Integrated Diagnostics | Series A | - |
1/2020 | BioIntervene | Series A | 30M |
11/2004 | Accelerator Corp. | Venture Round | 0 |
7/2002 | ARYx Therapeutics | Series C | 25M |
10/2009 | Xanodyne | Venture Round | 0 |
2/2008 | Epizyme | Series A | - |
7/2008 | Peptimmune | Series D | 8.9M |
4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
3/2020 | ElevateBio | Series B | 170M |
5/2003 | Quantum Dot | Series B | 1.5M |
12/2020 | Cullinan Oncology | Series C | 131.2M |
9/2019 | Repare Therapeutics | Series B | 82.5M |
2/2000 | DoubleTwist | Series D | 37M |
2/2015 | Chiasma | Series E | 70M |
11/2006 | Chiasma | Series C | 44M |
11/2020 | Umoja Biopharma | Series A | 53M |
6/2002 | MacroGenics | Venture Round | 12.6M |
6/2004 | ARYx Therapeutics | Series D | 55M |
1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
7/2005 | Affymax | Series D | 60M |
8/2022 | Orna Therapeutics | Series B | 0 |
8/2005 | Innovative Spinal Technologies | Series B | 39M |
6/2019 | Frontier Medicines | Series A | 67M |
7/2011 | Verastem Oncology | Series B | 32M |
6/2012 | Motus Therapeutics | Series B | 25M |
5/2005 | Cellerant Therapeutics | Series B | 16M |
4/2020 | ITeos Therapeutics | Series B | 0 |
12/2016 | TCR2 | Series A | 44.5M |
9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
3/2020 | ReCode Therapeutics | Series A | 0 |
3/2010 | Motus Therapeutics | Series A | 21M |
1/2002 | BioXell | Series A | 19.7M |
11/2008 | Pacira Pharmaceuticals | Series A | 85M |
9/2011 | Valeritas | Series C | 150M |
3/2008 | EKR Therapeutics | Series D | 50M |
4/2007 | Radius Health | Series B | 57.5M |
9/2007 | JapanBridge | Series A | 6.5M |
4/2019 | Dyne Therapeutics | Series A | 50M |
3/2015 | Clinical Ink | Venture Round | 20M |
1/2020 | Orna Therapeutics | Seed Round | 20M |
1/2011 | Aratana Therapeutics | Series A | 0 |
12/2002 | Intracel Holdings Corporation | Series B | 16M |
8/2015 | Syndax Pharmaceuticals | Series C | 0 |
12/2006 | NBI Development | Seed Round | 5.5M |
4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
6/2006 | VLST Corporation | Series B | 55M |
3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
4/2015 | True North Therapeutics | Series B | 35M |
10/2003 | Cotherix | Series C | 55M |
12/2021 | CODA Biotherapeutics | Venture Round | 0 |
9/2019 | Amphivena Therapeutics | Series C | 0 |
10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
3/2021 | Entrada Therapeutics | Series B | 0 |
7/2016 | Oncorus | Series A | 57M |
6/2017 | Repare Therapeutics | Series A | 68M |
2/2006 | Amphora Discovery | Series E | 4.4M |
9/2011 | Theraclone Sciences | Series B | 10.6M |
8/2010 | EndoGastric Solutions | Series F | 0 |
3/2009 | Surface Logix | Series E | 15M |
11/2012 | Motus Therapeutics | Series B | 8M |
3/2008 | TriVascular | Series A | 65M |
12/2012 | 23andMe | Series D | 50M |
1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
3/2015 | Vascular Pharmaceuticals | Series A | 9M |
6/2003 | Xoft | Series B | 0 |
10/2014 | Raze Therapeutics | Series A | 24M |
4/2003 | Epigenomics | Series C | 22.5M |
5/2007 | Portola Pharmaceuticals | Series C | 70M |
3/2005 | Humanigen | Series B | 20M |
6/2003 | EndoGastric Solutions | Series A | 5M |
4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
1/2009 | TaiGen Biotechnology | Series C | 0 |
3/2004 | TaiGen Biotechnology | Series B | 0 |
7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
6/2007 | Ceregene | Series C | 0 |
7/2011 | Radius Health | Series C | 66M |
5/2017 | Harpoon Therapeutics | Series B | 45M |
9/2004 | EndoGastric Solutions | Series B | 12M |
3/2013 | CoStim Pharmaceuticals | Series A | 22M |
11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
12/2011 | Aratana Therapeutics | Series B | 15M |
3/2007 | Theraclone Sciences | Series B | 29M |
8/2003 | Rinat Neuroscience | Series B | 40M |
9/2008 | Humanigen | Series D | 0 |
11/2019 | CODA Biotherapeutics | Series A | 15M |
5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
7/2011 | Nevro | Series B | 58M |
12/2011 | Radius Health | Private Equity Round | 21.4M |
10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
10/2009 | Epizyme | Series B | 32M |
4/2014 | Iconic Therapeutics | Series B | 20M |
6/2012 | TriVascular | Series D | 60M |
3/2018 | TCR2 | Series B | 0 |
3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
5/2003 | Accelerator Corp. | Venture Round | 0 |
7/2005 | Peptimmune | Series C | 20.4M |
10/2013 | Sideris Pharmaceuticals | Series A | 32M |
11/2010 | Aires Pharmaceuticals | Series B | 20M |
3/2009 | NeoVista | Series D | 18M |
5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
12/2005 | Hypnion | Series B | 0 |
7/2014 | Valeritas | Series D | 45M |
4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
11/2019 | SiO2 Materials Science | Venture Round | - |
8/2004 | Pharmasset | Series D | 40M |
9/2022 | Photys | Series A | 0 |
8/2022 | Aktis Oncology | Series A | 0 |
10/2021 | ReCode Therapeutics | Series B | 0 |
10/2021 | Protego Biopharma | Series A | 0 |
5/2023 | ReNAgade Therapeutics | Series A | 0 |
11/2019 | Werewolf Therapeutics | Series A | 0 |
11/2008 | Radius Health | Series C | 15M |
4/2007 | Xoft | Series D | 0 |
4/2007 | Syndax Pharmaceuticals | Series A | 40M |
3/2010 | Syndax Pharmaceuticals | Series A | 9M |
8/2013 | Syndax Pharmaceuticals | Series B | 0 |
5/2005 | Xoft | Series C | 0 |
6/2018 | Iconic Therapeutics | Venture Round | 0 |
7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
6/2012 | Astute Medical | Series C | 40.4M |
1/2016 | Tizona Therapeutics | Series A | 27M |
9/1999 | Pointshare | Series C | 40M |
11/2000 | Epigenomics | Venture Round | 24.1M |
7/2003 | Tercica | Series B | 44M |
5/2012 | Celladon | Venture Round | 10M |
5/2003 | BioXell | Series B | 19.9M |
10/2007 | Allozyne | Series B | 30M |
7/2013 | InformedDNA | Seed Round | 3M |
12/2005 | Allozyne | Series A | 3.5M |
3/2013 | Theraclone Sciences | Series B | 0 |
5/2009 | Elixir Pharmaceuticals | Series D | 12M |
3/2010 | Theraclone Sciences | Venture Round | 1.5M |
9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
10/2004 | MacroGenics | Series B | 30.5M |
3/2016 | Potenza Therapeutics | Venture Round | 30M |
9/2008 | ForteBio | Series C | 25M |
5/2006 | MacroGenics | Series C | 45M |
9/2001 | MacroGenics | Series A | 13.5M |
4/2007 | Cellerant Therapeutics | Series B | 0 |
6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
4/2001 | Genteric | Series B | 22M |
1/2023 | NextPoint Therapeutics | Series B | 0 |
12/2006 | Nevro | Seed Round | 5.5M |
9/2008 | Nevro | Series A | 21.8M |
4/2018 | Tetherex | Series B | 50M |
1/2010 | Alnara Pharmaceuticals | Series B | 35M |
11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
3/2004 | Cardiac Dimensions | Series C | 15M |
5/2023 | ElevateBio | Series D | 0 |
9/2010 | Motus Therapeutics | Series A | 19M |
1/2016 | Iconic Therapeutics | Series C | 40M |
3/2021 | ElevateBio | Series C | 525M |
8/2016 | Iconic Therapeutics | Series C | 10M |
5/2002 | AVEO Oncology | Series A | 15M |
7/2003 | Intercell | Series C | 50M |
2/2011 | NeoVista | Series E | 33M |
12/2004 | Amphora Discovery | Series C | 20M |
6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
6/2020 | Cullinan Oncology | Series B | 98.5M |
10/2017 | Cullinan Oncology | Series A | 150M |
6/2018 | ITeos Therapeutics | Series B | 0 |
8/2003 | Archus Orthopedics | Series B | 18M |
2/2012 | Helicos BioSciences | Series A | 27M |
1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
3/2003 | Peptimmune | Series B | 41.2M |
2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
6/2006 | Peptimmune | Series C | 0 |
8/2015 | Rhythm Metabolic | Series A | 40M |
8/2010 | TriVascular | Series C | 60M |
11/2009 | TriVascular | Series B | 30M |
3/2013 | Nevro | Series C | 0 |
12/2003 | Portola Pharmaceuticals | Series A | 21M |
11/2005 | Portola Pharmaceuticals | Series B | 46M |
11/2009 | Oxagen | Series C | 0 |
5/2009 | Proteon Therapeutics | Series B | 50M |
10/2007 | Acceleron Pharma | Series C | 31M |
7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
3/2021 | Aktis Oncology | Series A | 72M |
3/2001 | Pharmasset | Series C | 7.4M |
10/2003 | AVEO Oncology | Series B | 42.7M |
10/2014 | Atopix Therapeutics | Series A | 0 |
11/2011 | Verastem Oncology | Series C | 20M |
10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
11/2018 | Harpoon Therapeutics | Series C | 70M |
10/2004 | BioXell | Series C | 29M |
9/2012 | Vascular Pharmaceuticals | Series A | 16M |
5/2010 | Ntprx | Series B | 43M |
9/2016 | IOmx Therapeutics | Series A | 44.6M |
4/2004 | Corus Pharma | Series C | 0 |
11/2010 | iPierian | Series B | 29M |
9/2013 | iPierian | Venture Round | 30M |
12/2015 | True North Therapeutics | Series C | 40M |
7/2015 | Blade Therapeutics | Series A | 6.5M |
8/2019 | Oncorus | Series B | 0 |
6/2016 | Blade Therapeutics | Series B | 45M |
5/2014 | Proteon Therapeutics | Series D | 0 |
11/2013 | TriVascular | Series E | 0 |
1/2010 | Dragonfly Sciences | Venture Round | - |
8/2000 | Syrrx | Series A | 5.1M |
8/2020 | Dyne Therapeutics | Series B | 115M |
1/2005 | CHF Solutions | Venture Round | 22.9M |
11/2009 | EndoGastric Solutions | Series E | 0 |
3/2019 | TriNetX | Series D | 40M |
1/2002 | CryoCor | Series B | 12M |
10/2009 | EndoGastric Solutions | Venture Round | 0 |
2/2003 | Synergia Pharma | Series A | 2M |
5/2015 | Blade Therapeutics | Seed Round | - |
11/2006 | Solasia Pharma | Pre Seed Round | - |
9/2018 | CODA Biotherapeutics | Series A | 19M |
6/2002 | Cardiac Dimensions | Series B | 12M |
12/2006 | NeoVista | Series C | 41M |
6/2013 | Pierian Biosciences | Private Equity Round | 18M |
6/2007 | Athersys | Venture Round | 0 |
8/2011 | Proteon Therapeutics | Series C | 15.2M |
12/2007 | Cardiac Dimensions | Series D | 0 |
1/2002 | Archus Orthopedics | Series A | - |
3/2003 | Hypnion | Series B | 47.5M |
1/2011 | Mitobridge | Seed Round | - |
7/2021 | Frontier Medicines | Series B | 0 |
1/2021 | Werewolf Therapeutics | Series B | 0 |
3/2004 | Restore Medical | Series C | 26.5M |
12/2008 | Humanigen | Series D | 12M |
1/2008 | Peptimmune | Series D | 8.2M |
1/2012 | CoStim Pharmaceuticals | Seed Round | - |
11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
10/2004 | PharmAthene | Series B | 50M |
12/2019 | Triplet Therapeutics | Series A | 49M |
6/2014 | True North Therapeutics | Series A | 22M |
7/2007 | Xanodyne | Series A | 25M |
4/2004 | Affymax | Series C | 20M |
6/2005 | Verus Pharmaceuticals | Series A | 0 |
5/2003 | Cellerant Therapeutics | Series A | 10M |
7/2014 | Cerecor | Series B | 32M |
10/2015 | 23andMe | Series E | 115M |
5/2005 | Oxagen | Series B | 0 |
5/2001 | SenoRx | Venture Round | 19M |
9/2000 | CryoCor | Series A | 7M |
2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
1/2011 | 23andMe | Series C | 9M |
10/1999 | Pharmasset | Series B | 3.9M |
11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
9/2008 | Valeritas | Series A | 50M |
6/2003 | CryoCor | Series C | 27.5M |
11/2004 | Neosil | Series A | 32M |
3/2016 | Tizona Therapeutics | Series B | 43M |
10/2005 | Alinea Pharmaceuticals | Series A | 45M |
9/2008 | Innovative Spinal Technologies | Series C | 18M |
1/2006 | Xoft | Series C | 0 |
7/2004 | Arriva Pharmaceuticals | Series D | - |
3/2017 | Semma Therapeutics | Venture Round | - |
3/2006 | Helicos BioSciences | Series B | 40M |
1/2017 | Maverick Therapeutics | Venture Round | 125M |
1/2013 | Aratana Therapeutics | Series C | 0 |
6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
8/2004 | Ceregene | Series B | 32M |
11/2010 | Verastem Oncology | Series A | 16M |
7/2005 | Xanodyne | Series A | 170M |
2/2021 | Orna Therapeutics | Series A | 0 |
7/2012 | Chiasma | Series D | 38.5M |
10/2013 | Mitobridge | Series A | 0 |
9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
2/2006 | ARYx Therapeutics | Series E | 30.4M |
1/2004 | Amphora Discovery | Series B | 12.9M |
3/2015 | Semma Therapeutics | Series A | 44M |
8/2020 | Trishula Therapeutics | Funding Round | - |
12/2002 | Amphora Discovery | Series B | 12.5M |
6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
1/2006 | Archus Orthopedics | Series C | 35M |
5/2012 | NeoVista | Venture Round | 6M |
4/2013 | Radius Health | Private Equity Round | 43M |
4/2016 | Harpoon Therapeutics | Series A | 15M |
5/2023 | ReNAgade Therapeutics | Series A | 0 |
1/2023 | NextPoint Therapeutics | Series B | 0 |
9/2022 | Photys Therapeutics | Series A | 0 |
8/2022 | Aktis Oncology | Series A | 0 |
8/2022 | Orna Therapeutics | Series B | 0 |
12/2021 | CODA Biotherapeutics | Venture Round | 0 |
10/2021 | ReCode Therapeutics | Series B | 0 |
10/2021 | Protego Biopharma | Series A | 0 |
7/2021 | Frontier Medicines | Series B | 0 |
3/2021 | Entrada Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|